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Background. ‘‘FFM ME-TRAP’’ is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia
virus Ankara) delivering the pre-erythrocytic malaria antigen ME-TRAP. Over nine months follow-up in our original study, there
was no evidence that FFM ME-TRAP provided protection against malaria. The incidence of malaria was slightly higher in
children who received FFM ME-TRAP, but this was not statistically significant (hazard ratio 1.5, 95% CI 1.0-2.3). Although the
study was unblinded, another nine months follow-up was planned to monitor the incidence of malaria and other serious
adverse events. Methods and Findings. 405 children aged 1–6 yrs were initially randomized to vaccination with either FFM
ME-TRAP or control (rabies vaccine). 380 children were still available for follow-up after the first nine months. Children were
seen weekly and whenever they were unwell for nine months monitoring. The axillary temperature was measured, and blood
films taken when febrile. The primary analysis was time to parasitaemia .2,500/ml. During the second nine months monitoring,
49 events met the primary endpoint (febrile malaria with parasites .2,500/ml) in the Intention To Treat (ITT) group. 23 events
occurred among the 189 children in the FFM ME-TRAP group, and 26 among the 194 children in the control group. In the full
18 months of monitoring, there were 63 events in the FFM ME-TRAP group and 60 in the control group (HR=1.2, CI 0.84-1.73,
p=0.35). There was no evidence that the HR changed over the 18 months (test for interaction between time and vaccination
p=0.11). Conclusions. Vaccination with FFM ME-TRAP was not protective against malaria in this study. Malaria incidence
during 18 months of surveillance was similar in both vaccine groups. Trial Registration. Controlled-Trials.com
ISRCTN88335123
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INTRODUCTION
There were 515 million episodes of clinical P. falciparum malaria in
2002 [1]. Prime boost vaccination with FP9 (an attenuated fowlpox
virus) then modified vaccinia virus Ankara (MVA), both recombi-
nant for the pre-erythrocytic antigen construct ME-TRAP (the
Multiple Epitope string and Thrombospondin Related Adhesion
Protein, ME- TRAP [2]) is safe, immunogenic and partially
protective inmalaria-naı ¨ve adults exposed to experimental challenge
[3]. We previously conducted a Phase 2b study of the FFM ME-
TRAP regimen (i.e. two sequential FP9 ME-TRAP vaccinations
followed by MVA ME-TRAP) to assess efficacy in children living in
rural Kenya, and have reported the primary analysis [4]. Local and
systemic reactogenicity was mild. Immunogenicity was lower than
that seen among partially protected volunteers in sporozoite chal-
lenge studies [3] and earlier phase 1 studies of children at lower
malaria transmission intensities [5]. There was no evidence of pro-
tection against malaria, (the incidence was higher among children
vaccinated with FFM ME-TRAP, but this difference was not
significant (the hazard ratio was 1.5, 95% CI 1.0-2.3, P=0.14) [4].
Although the study was unblinded at 9 months for the primary
analysis of efficacy, the analysis plan specified continued
surveillance for serious adverse events and malaria for a further
period of 9 months.
METHODS
The protocols for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1,
Protocols S1, S2, S3, and Analysis Plan S1.
Study Design
The study was randomised, controlled and double blind. Details of
ethical approval are described previously [4].
405 children were randomized, and all received at least one
dose of vaccine. Children were screened in February 2005,
immunised between March 2005 and May 2005, and followed up
until February 2006, when the study was unblinded. A further
9 months follow up was conducted on 387 children who were still
available, until November 2006. No further cross-sectional bleeds
were taken during this time.
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The participating children were aged 1–6 years old when
randomized in February 2005, healthy, and resident in the study
area.
Location
The study was carried out in Junju sublocation in Kilifi District, on
the Kenyan coast, as described previously [4].
Interventions
The trial vaccination regimen was a candidate prime boost
malaria vaccination. Details have been described previously [4].
Briefly, two sequential FP9 ME-TRAP vaccinations (5610
7
plaque forming units) followed by MVA ME-TRAP vaccination
(1.5610
8 plaque forming units), given intradermally. The control
was rabies vaccine (Aventis Pasteur, WISTAR strain), adminis-
tered according to the same timings. Rabies was also given
intradermally, at 0.25 IU. Vaccinations were spaced 4 weeks apart
(acceptable range 3–5 weeks).
Objectives
The objectives of this extension of the original Phase 2b trial were
to describe the distribution of febrile malaria by vaccination group,
and to assess any latent safety issues.
Outcomes
Efficacy (Malaria episodes)
The primaryendpointwasa clinical episode ofmalaria,definedas
an axillary temperature greater than 37.5 degrees centigrade, with
a Plasmodium falciparum parasitaemia greater than 2,500 parasites per
ul. Episodes of malaria were identified as described previously [4].
Randomization
Full details of randomization have been described previously [4].
Briefly, the investigators in Kenya enrolled children, and applied
study numbers sequentially. A list of eligible children was ordered
according to age and village, and matched to the list of
randomization card numbers, generated in the UK.
Blinding
The nurses who administered vaccinations did not take part in any
other trial related procedure, and were subsequently based in Kilifi
District Hospital rather than the trial site. They drew up
vaccinations according to the instructions in the randomisation
envelope, and documented the vaccination in notes that were not
available to the investigators until after unblinding
After the first 9 months monitoring the primary analysis was
conducted. A cleaned, locked database was transmitted to the
DSMB, and the statistician then transmitted the allocation code to
the lead investigator, who then implemented the analysis plan. It
was planned to conduct a further analysis of episodes of malaria
after a further 9 months monitoring, despite having unblinded the
trial. The results (no significant efficacy) were fed back to the study
participants, and a strong view was expressed that study
participants wished to be told which vaccines children had
received. This was done. Continued monitoring was supervised by
a second investigator, and the lead investigator played no further
part in assessment of malaria episodes or collection of data. The
second investigator did not have details of vaccination allocation,
neither did the laboratory staff who read blood films. Data was
cleaned by the second investigator before being locked, following
which analysis was conducted by the lead investigator.
Statistical methods
The analysis plan was approved by the DSMB. The primary
analysis was a log rank test comparing the time to the first or only
episode of malaria (defined as fever with parasitaemia above
2500/mL) between the vaccination groups, stratified by age group,
ITN (insecticide treated net) use and village, analysed by Intention
To Treat. The hazard ratio and 95% confidence interval was
estimated by Cox’s regression adjusted for the same covariates.
Age group was a categorical variable with three levels (1–2 years
old, 2–5 years old, 5–6 years old). Village had 5 levels. ITN use
was defined as sleeping under a treated net every night, which had
less than three holes into which a finger could comfortably fit.
Poisson regression was used to estimate the incidence rate ratio
taking into account all malaria episodes, adjusted for the same
covariates. A period of 28 days after each malaria episode was
deducted from the person time at risk, since individuals were
assumed not to be at risk of malaria during this period. No further
analysis is planned.
In order to assess interactions, data from each individual was
split according to monitoring period. An interaction between
vaccination and time of monitoring (first 9 months vs second
9 months) was then assessed for poisson regression and for survival
analysis. Models with this interaction were compared with models
without an interaction term using the likelihood ratio test.
RESULTS
Participant flow
405 children were randomized in May 2005, and 383 were still
available for follow up after the first 9 months (Figure 1). 333
completed the second 9 months follow up.
Baseline data
The treatment allocation groups at the start of the second
9 months monitoring were still well balanced with respect to
baseline characteristics (Table 1).
Numbers analyzed
Of the 383 children followed up in the second 9 months, 342 were
from the original According To Protocol analysis group. All 383
were part of the Intention To Treat group.
Outcomes and estimation
The primary analysis for this study has already been conducted
[4]. During the second 9 months monitoring, there were 49 events
that met the primary endpoint (febrile malaria with parasites
.2,500/ml) in the ITT group. 23 of these occurred among the 189
children in the FFM ME-TRAP group, and 26 among the 194
children in the rabies control group (logrank test p=0.59, p=0.67
when stratified by age, village and ITN use). In the full 18 months
of monitoring, there were 63 events in the FFM ME-TRAP group
and 60 in the control group (p=0.46, p=0.35 when stratified by
covariates). A Kaplan Meier plot of the ITT group is shown in
figure 2.
When analysis was restricted According To Protocol, there were
52 events among 170 children in the FFM ME-TRAP group,
compared with 54 among 172 children in the rabies control group
(p=0.94, p=0.95 adjusted).
Survival Analysis (Cox Regression)
The hazard ratio (HR) for the effect of vaccination, estimated
using Cox regression, was 1.2 (95% CI 0.84-1.73, p=0.35) over
the full 18 months of monitoring. The HR during the first
ME-TRAP Vaccine Follow-Up
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p=0.59) during the second 9 months. When analysis was
restricted to ATP, the HRs were 1.06 (0.72–1.56 p=0.94), 1.31
(0.83–2.08, p=0.35) and 0.72 (0.39–1.34, p=0.31) for the full
18 months, first 9 months and second 9 months monitoring,
respectively. The difference in HRs between the two time periods
was not statistically significant (the likelihood ratio test for the
interaction between time period and vaccination group gave
p=0.11 and p=0.15 for ITT and ATP analyses respectively).
Multiple Episodes
During 18 months monitoring of the ITT cohort there were 170
episodes of febrile malaria with parasitaemia .2,500/ml among
383 children. This comprised 0.35 episodes per Person Year At
Risk among children given FFM ME-TRAP, and 0.29 among
children given the control vaccination.
The Incidence Rate Ratios for the effect of vaccination were
1.06 (CI 0.76-1.48, p=0.75) during the first 18 months, 1.58 (CI
1.08-2.32, p=0.017) during the first 9 months and 0.8 (0.46–1.36,
p=0.42) during the second 9 months. Among the ATP cohort the
IRRs were 1.06 (0.76–1.48, p=0.75), 1.36 (0.89–2.06, p=0.16)
and 0.67 (0.38–1.19, p=0.17) for the full 18 months, first
9 months and second 9 months monitoring, respectively. The
likelihood ratio test for the interaction between vaccine group and
time period gave p=0.051 and p=0.093 for ITT and ATP
analysis respectively.
Adverse Events
8 Further serious adverse events were detected during the second
9 months of follow up. Among FFM ME-TRAP vaccinees there
were episodes of pneumonia, dysentery, malaria with multiple
seizures and a snake bite which required hospital admissions.
Among control vaccinees there were two episodes of gastroenteritis
with dehydration, an episode of malaria with multiple seizures and
Figure 1. Trial Profile. After screening for eligibility, parents were invited to bring their children back to the dispensary for immunisation. Children
were randomized on attending for vaccination. Of the 17 children who attended for the first, but not the final, vaccination, two had moved out of the
area, and parents of the remaining 15 chose not to reattend. No severe adverse events were identified in this children. 8 children moved out of the
area before 9 months monitoring was complete.
doi:10.1371/journal.pone.0000707.g001
Table 1. Covariates by vaccination group at the beginning of
the second 9 months monitoring.
......................................................................
FFM ME-TRAP Rabies
Village
Gongoni 36 40
Junju 50 50
Kolewa 49 56
Mapawa 39 32
Mwembe tsungu 15 16
Age Cat (years)
1–2 36 41
2–5 106 106
5–7 47 47
Bednet*
Without 75 70
With 113 123
doi:10.1371/journal.pone.0000707.t001
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PLoS ONE | www.plosone.org 3 August 2007 | Issue 8 | e707a Stevens Johnson reaction (associated with co-trimoxazole use).
All adverse events resolved without sequelae, and there were no
deaths in either group.
DISCUSSION
Interpretation
We have previously reported the primary analysis after 9 months
post-vaccination monitoring for episodes of malaria [4], during
which there was no evidence of protection against malaria. The
incidence was higher among children vaccinated with FFM ME-
TRAP, but this difference was not significant. We report here
a further 9 months monitoring of the same children, during which
the incidence of malaria episodes was similar in both groups.
The primary analysis considers time to first episode. In this
analysis children do not contribute further to the analysis after an
episode of malaria, which could potentially cause a bias in the
estimation of the hazardratio inthe second period.However,similar
results were obtained when multiple episodes were analyzed.
The primary analysis had already been conducted. The analysis
here is therefore considered secondary. Furthermore, these data
were acquired after the study had been unblinded. Measures were
taken to reduce the impact of this on the integrity of the study; an
investigator not involved in the primary analysis oversaw the
second 9 months of monitoring, and blood films were read in the
laboratory with reference to only study subject numbers without
knowledge of vaccination group. The lead investigator who had
conducted the primary analysis was not involved in continued
follow up, and conducted the analysis presented here after being
sent a cleaned database. That no efficacy was seen on the primary
analysis was communicated to study participants, and so vaccine
allocation was perhaps unlikely to bias health seeking behaviour. A
similar number of follow up visits were completed among children
allocated to either vaccination (4,958 visits among FFM ME-
TRAP vaccinees vs 5,130 among controls), and a similar number
presented for assessment of fever between visits (1,086 among
FFM ME-TRAP vaccinees vs 1,095 among controls), p=0.58).
Nevertheless, a subtle impact on health seeking behaviour cannot
be excluded, and our findings here must be treated with
appropriate caution.
Borderline significance on log likelihood testing for interactions
between monitoring period and vaccination was seen. However,
this was one of multiple analyses for interactions. The other 3 tests
yielded less significant findings, and the study was no longer blind.
There is insufficient evidence to conclude there might have been
an interaction between vaccination and time (i.e. the effect, or lack
of effect, of vaccination was constant throughout the duration of
the study). This suggests that the variations in hazard during the
monitoring period probably represent chance alone.
After the primary analysis of this trial we considered the formal
possibilitythat transforminggrowthfactorb production [6] and anti-
inflammatory responses [7] induced by vaccination might increase
susceptibility to malaria. However, there was no indication that
higher T cell responses predicted greater susceptibility to malaria,
suggesting that there was not a causal link, and the increase in risk
was not significant during primary analysis [4]. The convergence of
Incidence Rates and Hazards seen during the second 9 months of
monitoring provides further reassurance. Since the vaccinated
children are now aged 3–8 years, and the incidence of malaria is
expected to be lower still, continued analysis of episodes of malaria
by vaccination group is not planned.
SUPPORTING INFORMATION
Protocol S1 Protocol Under Which Further 9 Months Follow
up was Conducted
Found at: doi:10.1371/journal.pone.0000707.s001 (4.42 MB
PDF)
Protocol S2 Protocol for ongoing study
Found at: doi:10.1371/journal.pone.0000707.s002 (4.42 MB
DOC)
Figure 2. Primary analysis of efficacy. The probability of remaining free of clinical malaria is plotted over the 18 months of monitoring (ITT analysis).
Numbers of children at risk are given below the Kaplan Meier plot. The endpoint is .2,500 parasites per microlitre and fever. HR=0.84, 95% CI 0.47-
1.49, p=0.59
doi:10.1371/journal.pone.0000707.g002
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Found at: doi:10.1371/journal.pone.0000707.s003 (0.31 MB
DOC)
Analysis Plan S1 Analysis Plan for second 9 months follow up
Found at: doi:10.1371/journal.pone.0000707.s004 (0.03 MB
DOC)
Checklist S1 CONSORT checklist
Found at: doi:10.1371/journal.pone.0000707.s005 (0.05 MB
DOC)
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